Literature DB >> 19568693

Semiparametric distributions with estimated shape parameters.

Klas J F Petersson1, Eva Hanze, Radojka M Savic, Mats O Karlsson.   

Abstract

PURPOSE: To investigate the use of adaptive transformations to assess the parameter distributions in population modeling.
METHODS: The logit, box-cox, and heavy tailed transformations were investigated. Each one was used in conjunction with the standard (exponential) transformation for PK and PD parameters. The shape parameters of these transformations were estimated to allow the parameter distributions to more accurately resemble a wider range of parameter distributions. The transformations were tested both in simulated settings where the true distributions were known and in 30 models developed from real data.
RESULTS: In the simulated setting the transformations were better than the standard lognormal distribution at characterizing the true distributions. Improvement could also be seen in objective function value (OFV) and in simulation based diagnostics. In the real datasets, significant model improvement based on OFV could be seen in 22, 18, and 22 out of the 30 models for the three transformations respectively.
CONCLUSION: Transformations with estimated shape parameters are a promising approach to relax the often erroneous assumption of a known shape of the parameter distribution. They offer a simple and straightforward way of handling and characterizing parameter distributions.

Entities:  

Mesh:

Year:  2009        PMID: 19568693     DOI: 10.1007/s11095-009-9931-1

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  26 in total

1.  Assessment of type I error rates for the statistical sub-model in NONMEM.

Authors:  Ulrika Wählby; M René Bouw; E Niclas Jonsson; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-06       Impact factor: 2.745

2.  Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients.

Authors:  Justin J Wilkins; Grant Langdon; Helen McIlleron; Goonaseelan Colin Pillai; Peter J Smith; Ulrika S H Simonsson
Journal:  Eur J Clin Pharmacol       Date:  2006-05-10       Impact factor: 2.953

3.  Model of chemotherapy-induced myelosuppression with parameter consistency across drugs.

Authors:  Lena E Friberg; Anja Henningsson; Hugo Maas; Laurent Nguyen; Mats O Karlsson
Journal:  J Clin Oncol       Date:  2002-12-15       Impact factor: 44.544

4.  A new method to explore the distribution of interindividual random effects in non-linear mixed effects models.

Authors:  K E Fattinger; L B Sheiner; D Verotta
Journal:  Biometrics       Date:  1995-12       Impact factor: 2.571

5.  The importance of modeling interoccasion variability in population pharmacokinetic analyses.

Authors:  M O Karlsson; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1993-12

6.  Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis.

Authors:  Marie Cullberg; Ulf G Eriksson; Karin Wåhlander; Henry Eriksson; Sam Schulman; Mats O Karlsson
Journal:  Clin Pharmacol Ther       Date:  2005-04       Impact factor: 6.875

7.  Evaluation of Bayesian estimation in comparison to NONMEM for population pharmacokinetic data analysis: application to pefloxacin in intensive care unit patients.

Authors:  R Bruno; M C Iliadis; B Lacarelle; V Cosson; J W Mandema; Y Le Roux; G Montay; A Durand; M Ballereau; M Alasia
Journal:  J Pharmacokinet Biopharm       Date:  1992-12

8.  Intravenously administered digoxin in patients with acute atrial fibrillation: a population pharmacokinetic/pharmacodynamic analysis based on the Digitalis in Acute Atrial Fibrillation trial.

Authors:  Björn Hornestam; Markus Jerling; Mats O Karlsson; Peter Held
Journal:  Eur J Clin Pharmacol       Date:  2003-02-19       Impact factor: 2.953

9.  Comparison of cytotoxicity of 2-chloro- 2'-arabino-fluoro-2'-deoxyadenosine (clofarabine) with cladribine in mononuclear cells from patients with acute myeloid and chronic lymphocytic leukemia.

Authors:  Synnöve Lindemalm; Jan Liliemark; Astrid Gruber; Staffan Eriksson; Mats O Karlsson; Yuying Wang; Freidoun Albertioni
Journal:  Haematologica       Date:  2003-03       Impact factor: 9.941

10.  Application of population pharmacokinetics to cladribine.

Authors:  Synnöve Lindemalm; Radojka M Savic; Mats O Karlsson; Gunnar Juliusson; Jan Liliemark; Freidoun Albertioni
Journal:  BMC Pharmacol       Date:  2005-03-09
View more
  35 in total

1.  Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults.

Authors:  Lena E Friberg; Patanjali Ravva; Mats O Karlsson; Ping Liu
Journal:  Antimicrob Agents Chemother       Date:  2012-03-19       Impact factor: 5.191

2.  Transforming parts of a differential equations system to difference equations as a method for run-time savings in NONMEM.

Authors:  K J F Petersson; L E Friberg; M O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-09-29       Impact factor: 2.745

3.  Evaluation of Approaches to Deal with Low-Frequency Nuisance Covariates in Population Pharmacokinetic Analyses.

Authors:  Chakradhar V Lagishetty; Stephen B Duffull
Journal:  AAPS J       Date:  2015-06-26       Impact factor: 4.009

4.  Inter-study variability of preclinical in vivo safety studies and translational exposure-QTc relationships--a PKPD meta-analysis.

Authors:  V Gotta; F Cools; K van Ammel; D J Gallacher; S A G Visser; F Sannajust; P Morissette; M Danhof; P H van der Graaf
Journal:  Br J Pharmacol       Date:  2015-07-21       Impact factor: 8.739

5.  Evaluation of the long-term durability and glycemic control of fasting plasma glucose and glycosylated hemoglobin for pioglitazone in Japanese patients with type 2 diabetes.

Authors:  Frances Stringer; Joost DeJongh; Kazuaki Enya; Emiko Koumura; Meindert Danhof; Kohei Kaku
Journal:  Diabetes Technol Ther       Date:  2014-12-22       Impact factor: 6.118

6.  Population pharmacokinetic analysis of voriconazole from a pharmacokinetic study with immunocompromised Japanese pediatric subjects.

Authors:  Chieko Muto; Satoshi Shoji; Yoshiro Tomono; Ping Liu
Journal:  Antimicrob Agents Chemother       Date:  2015-03-23       Impact factor: 5.191

7.  The variability in beta-cell function in placebo-treated subjects with type 2 diabetes: application of the weight-HbA1c-insulin-glucose (WHIG) model.

Authors:  Janna K Duong; Willem de Winter; Steve Choy; Nele Plock; Himanshu Naik; Walter Krauwinkel; Sandra A G Visser; Katia M Verhamme; Miriam C Sturkenboom; B H Stricker; Meindert Danhof
Journal:  Br J Clin Pharmacol       Date:  2016-11-17       Impact factor: 4.335

8.  Population Pharmacokinetic and Exposure-Response Analyses of Prasugrel in Pediatric Patients with Sickle Cell Anemia.

Authors:  Brian A Moser; Elizabeth S LaBell; Emmanuel Chigutsa; Joseph A Jakubowski; David S Small
Journal:  Clin Pharmacokinet       Date:  2018-02       Impact factor: 6.447

9.  Population pharmacokinetic and pharmacodynamic properties of intramuscular quinine in Tanzanian children with severe Falciparum malaria.

Authors:  Ilse C E Hendriksen; Deogratius Maiga; Martha M Lemnge; George Mtove; Samwel Gesase; Hugh Reyburn; Niklas Lindegardh; Nicholas P J Day; Lorenz von Seidlein; Arjen M Dondorp; Joel Tarning; Nicholas J White
Journal:  Antimicrob Agents Chemother       Date:  2012-11-26       Impact factor: 5.191

10.  Population pharmacokinetics-pharmacodynamics of oral everolimus in patients with seizures associated with tuberous sclerosis complex.

Authors:  François Pierre Combes; Guillaume Baneyx; Neva Coello; Penny Zhu; William Sallas; Hequn Yin; Jerry Nedelman
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-07-10       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.